Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003569
Abstract: Background The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis. We report results from a phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced… read more here.
Keywords: aflibercept plus; ziv; ziv aflibercept; plus pembrolizumab ... See more keywords